A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and...

Area of Science:

• Pharmacology
• Urology
• Clinical Trials

Background:

• Erectile dysfunction (ED) affects a significant number of men globally.
• Sildenafil and tadalafil are common phosphodiesterase type 5 inhibitors used for ED treatment.
• Dosing instructions differ between sildenafil and tadalafil, potentially influencing patient adherence and preference.

Purpose of the Study:

• To compare patient preference between sildenafil and tadalafil for ED treatment.
• To assess patient preference for tadalafil's dosing instructions versus sildenafil's dosing instructions during tadalafil therapy.

Main Methods:

• A randomized, double-blind, crossover study was conducted with 219 patients for drug preference and 46 for dosing instruction preference.
• Patients received either sildenafil 50 mg or tadalafil 20 mg with their respective dosing instructions.
• A unique sham placebo methodology was used to maintain blinding due to differing dosing regimens.

Main Results:

• 73% of evaluable patients (132/181) preferred tadalafil over sildenafil for ED treatment.
• 67% of evaluable patients (24/36) preferred tadalafil's dosing instructions when using tadalafil.
• Both sildenafil and tadalafil were well-tolerated by study participants.

Conclusions:

• Tadalafil, with its associated dosing instructions, was preferred by a significant majority of patients over sildenafil.
• Patient preference for tadalafil and its dosing instructions suggests potential benefits in treatment adherence and satisfaction.
• The findings support tadalafil as a preferred ED treatment option based on patient preference in the studied doses.